Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS–TIMI 54 - ScienceDirect
Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54 | Journal of the American Heart Association
![PDF] Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54 | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/cfb28c5737c40589e026a13b4dcce810fc8777f3/5-Figure2-1.png "PDF] Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54 | Semantic Scholar")
PDF] Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54 | Semantic Scholar
![PDF] Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/0481a5638e69a8039cd62b6f882832b7e1b98346/4-Figure1-1.png "PDF] Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. | Semantic Scholar")
PDF] Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. | Semantic Scholar
Nghiên cứu phòng ngừa biến cố tim mạch trên bệnh nhân có tiền căn nhồi máu cơ tim đang sử dụng aspirin bằng ticagrelor so với giả dược: Cơ sở lý luận
Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54 | tctmd.com
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS- TIMI. - ppt download
Presentazione standard di PowerPoint
Baseline patient characteristic in the PEGASUS-TIMI 54 trial and the... | Download Table
Implications of the PEGASUS-TIMI 54 trial for US clinical practice | Open Heart
Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations | The BMJ
PDF) Implications of the PEGASUS-TIMI 54 trial for US clinical practice
PEGASUS-TIMI 54: la duplice antiaggregazione con aspirina e ticagrelor a lungo termine riduce gli eventi trombotici ma aumenta le emorragie in pazienti con pregresso infarto miocardico - CardioInfo
Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program | Future Cardiology
Abstract 16658: Patient Selection for Long-Term Secondary Prevention With Ticagrelor: Insights From PEGASUS-TIMI 54 | Circulation
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction | NEJM
Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial -
Abstract 211: Implications of the PEGASUS-TIMI 54 Trial for U.S. Clinical Practice | Circulation: Cardiovascular Quality and Outcomes
Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54 | Journal of the American Heart Association
Reduction in Ischemic Events with Ticagrelor in Diabetic Patients from the PEGASUS-TIMI 54 Trial Deepak L. Bhatt, MD, MPH, Marc P. Bonaca, MD, MPH, Sameer. - ppt download
Implications of the PEGASUS-TIMI 54 trial for US clinical practice | Open Heart
PEGASUS-TIMI 54 – TIMI STUDY GROUP
Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54 | Journal of the American Heart Association
Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease - ScienceDirect
PEGASUS TIMI 54
PEGASUS TIMI 54 – SIAC
